MX2024006360A - Celula t controlable por inducibilidad humana y metodo para prepararla. - Google Patents

Celula t controlable por inducibilidad humana y metodo para prepararla.

Info

Publication number
MX2024006360A
MX2024006360A MX2024006360A MX2024006360A MX2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A MX 2024006360 A MX2024006360 A MX 2024006360A
Authority
MX
Mexico
Prior art keywords
positivity
cell
human
inducibility
controllable
Prior art date
Application number
MX2024006360A
Other languages
English (en)
Spanish (es)
Inventor
Shimon Sakaguchi
Norihisa Mikami
Original Assignee
Regcell Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regcell Co Ltd filed Critical Regcell Co Ltd
Publication of MX2024006360A publication Critical patent/MX2024006360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2024006360A 2021-11-24 2022-11-22 Celula t controlable por inducibilidad humana y metodo para prepararla. MX2024006360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021190127 2021-11-24
PCT/JP2022/043220 WO2023095801A1 (ja) 2021-11-24 2022-11-22 ヒト誘導性制御性ｔ細胞およびその作製方法

Publications (1)

Publication Number Publication Date
MX2024006360A true MX2024006360A (es) 2024-08-19

Family

ID=86539488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006360A MX2024006360A (es) 2021-11-24 2022-11-22 Celula t controlable por inducibilidad humana y metodo para prepararla.

Country Status (9)

Country Link
US (1) US20250018033A1 (https=)
EP (1) EP4438722A4 (https=)
JP (3) JP7572755B2 (https=)
KR (1) KR20240116751A (https=)
CN (1) CN118591619A (https=)
CA (1) CA3239019A1 (https=)
MX (1) MX2024006360A (https=)
TW (1) TW202330911A (https=)
WO (1) WO2023095801A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250352578A1 (en) * 2021-11-24 2025-11-20 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing t cell-related disorders
EP4663195A1 (en) * 2023-02-08 2025-12-17 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing pemphigus
WO2024204553A1 (ja) * 2023-03-29 2024-10-03 レグセル株式会社 ヒト誘導性制御性ｔ細胞およびその作製方法、およびｔ細胞関連疾患を治療または予防するための医薬組成物
CN116640728B (zh) * 2023-07-24 2023-10-20 呈诺再生医学科技(北京)有限公司 RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用
JP2025064863A (ja) * 2023-10-06 2025-04-17 株式会社マイオリッジ Ｔ細胞の培養方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
US20140309224A1 (en) 2011-09-13 2014-10-16 Roninson Igor B TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
UA117342C2 (uk) 2012-02-02 2018-07-25 Сенекс Біотекнолоджи Інк. Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку
EP2888232A1 (en) 2012-08-23 2015-07-01 F. Hoffmann-La Roche AG Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
ES2698960T3 (es) 2012-10-08 2019-02-06 Merck Patent Gmbh Compuestos de 2-aminopiridina
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
JP2016501251A (ja) 2012-12-10 2016-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための新規二環フェニル−ピリジン／ピラジン
WO2014106606A1 (en) 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
WO2014154723A1 (en) 2013-03-29 2014-10-02 F. Hoffmann-La Roche Ag Novel pyrrole derivatives for the treatment of cancer
WO2014194245A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
TW201605857A (zh) 2013-10-03 2016-02-16 赫孚孟拉羅股份公司 Ｃｄｋ８之醫療性抑制劑及其用途
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
JP6434989B2 (ja) 2014-03-27 2018-12-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリジルピペリジン
JP6521387B2 (ja) 2014-04-18 2019-05-29 武田薬品工業株式会社 縮合複素環化合物
EP3205645B1 (en) 2014-04-18 2019-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
JP6987338B2 (ja) * 2016-08-05 2021-12-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＭＨＣＩＩ拘束性ＣＤ４＋ＦＯＸＰ３＋制御性Ｔ細胞のｅｘ ｖｉｖｏ生成及びその治療的使用
CA3051469A1 (en) * 2017-01-27 2018-08-02 Abraham J And Phyllis Katz Cord Blood Foundation T cells derived from umbilical cord blood
US11578067B2 (en) 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
US20210238551A1 (en) * 2018-08-22 2021-08-05 Osaka University Method for Generating Regulatory T Cells
EP3880213A4 (en) * 2018-11-13 2022-11-23 Abraham J and Phyllis Katz Cord Blood Foundation T CELLS WITH IMPROVED MITOCHONDRIAL FUNCTION
US20220018835A1 (en) * 2018-12-07 2022-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
CA3140904A1 (en) * 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
AU2020380072B2 (en) * 2019-11-08 2025-11-27 Good T Cells, Inc. Epitope of regulatory T cell surface antigen, and antibody specifically binding thereto
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
US20210374678A1 (en) 2020-05-29 2021-12-02 Delta Pds Co., Ltd. Kanban-based work processing device and work processing method
CN115768870A (zh) * 2020-06-01 2023-03-07 促进军事医学的亨利·M·杰克逊基金会公司 诱导型调节性t细胞，其生产方法及其用途
US20250352578A1 (en) * 2021-11-24 2025-11-20 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing t cell-related disorders
EP4532697A2 (en) * 2022-06-03 2025-04-09 Beam Therapeutics Inc. Modified regulatory t cells and methods of using the same
EP4596684A1 (en) * 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)

Also Published As

Publication number Publication date
CA3239019A1 (en) 2023-06-01
JP7759136B2 (ja) 2025-10-23
EP4438722A4 (en) 2025-10-22
US20250018033A1 (en) 2025-01-16
EP4438722A1 (en) 2024-10-02
JP7572755B2 (ja) 2024-10-24
JP2025004140A (ja) 2025-01-14
KR20240116751A (ko) 2024-07-30
WO2023095801A1 (ja) 2023-06-01
CN118591619A (zh) 2024-09-03
JP2026009980A (ja) 2026-01-21
TW202330911A (zh) 2023-08-01
JPWO2023095801A1 (https=) 2023-06-01

Similar Documents

Publication Publication Date Title
MX2024006360A (es) Celula t controlable por inducibilidad humana y metodo para prepararla.
CY1124717T1 (el) Μεθοδοι, kit και συσκευη για επεκταση πληθυσμου κυτταρων
Wingender et al. OMIP-030: Characterization of human T cell subsets via surface markers
CY1123497T1 (el) Συστηματα που παρεχουν μiκροσκοπικες εικονες τουλαχιστον μιας ανατομικης δομης σε μια συγκεκριμενη αναλυση
CO2021001064A2 (es) Método para la producción de las células t gamma delta
MX2020009272A (es) Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
BR112019016672A8 (pt) Método para gerar progenitores de células t
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
MX341517B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
MX2024006370A (es) Composicion farmaceutica para tratar o prevenir trastornos relacionados con celulas t.
EP4513175A3 (en) Optical systems and methods for biological analysis
AR085409A1 (es) Firmas microbianas como indicadores de exposicon a radiacion
WO2020061251A8 (en) High throughput method and system for mapping intracellular phase diagrams
MX2021015620A (es) Célula para resistir reacción al trasplante y método.
MX2020001920A (es) Metodos de inactivacion de contaminantes virales.
MX2022016266A (es) Metodos y sistemas para pruebas no destructivos (pnd) con procesamiento basado en inteligencia artificial entrenada.
MX2020009760A (es) Monitoreo y cuantificacion celular biofisicos y bioquimicos avanzados usando citologia de fuerza laser.
MX2015011032A (es) Recubrimientos de catalizador porosos.
UY40565A (es) Inhibidores de la PCSK9 y métodos de uso de los mismos
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
MX2013010997A (es) Ensayo para clasificacion de compuestos que disminuyen selectivamente el numero de celulas madre de cance.
CU23896B1 (es) Método para inhibir la replicación del vih en células de mamíferos
CR20220288A (es) Anticuerpos contra integrina alfa 11 beta 1
CO2024003965A2 (es) Iniciar una transmisión de una pequeña cantidad de datos basada en una o más condiciones específicas del tipo de dispositivo
MX2020005562A (es) Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.